Cargando…
Review of tenofovir-emtricitabine
Highly active antiretroviral therapy has significantly reduced HIV-related morbidity and mortality. Increasingly, fixed-dose antiretroviral combinations with equal or greater potency than traditional antiretrovirals, along with fewer side effects, reduced toxicity, and simplified dosing convenience...
Autores principales: | Masho, Saba Woldemichael, Wang, Cun-Lin, Nixon, Daniel E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387297/ https://www.ncbi.nlm.nih.gov/pubmed/18516268 |
Ejemplares similares
-
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018) -
Eosinophilic Colitis Associated with Emtricitabine/Tenofovir
por: Lozier, Matthew R, et al.
Publicado: (2018) -
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021) -
Acute Liver Toxicity due to Efavirenz/Emtricitabine/Tenofovir
por: Patil, Rashmee, et al.
Publicado: (2015) -
Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)